MaxCyte (MXCT)
(Delayed Data from NSDQ)
$2.04 USD
-0.02 (-0.97%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $2.05 +0.01 (0.49%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MXCT 2.04 -0.02(-0.97%)
Will MXCT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MXCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MXCT
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT)
MXCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround
MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
Other News for MXCT
MaxCyte (MXCT) Partners with Anocca AB in Licensing Deal
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell ...
MaxCyte announces strategic platform licensing agreement with Anocca AB
MaxCyte (MXCT) Receives "Overweight" Rating and New Price Target from Stephens & ...
MaxCyte (MXCT) Gains Overweight Rating with Promising Growth Outlook | MXCT Stock News